MONTREAL, QUEBEC--(Marketwire - April 03, 2008) - Alethia Biotherapeutics announces that it has secured C$2.4 M in financing from BDC Venture Capital and GO Capital Fund. This investment will allow Alethia to initiate the pre-clinical development of therapeutic monoclonal antibodies for the treatment and prevention of severe bone loss, ovarian cancer, and metastatic breast cancer, indications for which there are currently few therapeutic options.
